LEGAL REQUIREMENTS FOR PARALLEL IMPORT OF MEDICINAL PRODUCTS FOR HUMAN USE LICENSE ISSUANCE AND POTENTIAL BARRIERS FOR PARALLEL TRADE IN THE REPUBLIC OF LITHUANIA

Mindaugas Zalepūga
Mykolas Romeris University, Faculty of Law, Department of Philosophy of Law and Legal History
Ateities 20, LT-08303, Vilnius,
Telephone: (+370) 527 14637
E-mail: mindaugas.zalepuga@gmail.com

Received on 26 September, 2013; accepted 29 October, 2013
doi:10.13165/SMS-13-5-4-15

Annotation. Parallel import of medicinal products is being defined as an import into the Republic of Lithuania outside the distribution network of the authorised distributor of the product granted marketing authorisation in another EEA Member State, which is identical to the medicinal product already granted marketing authorisation in the Republic of Lithuania or sufficiently resembling it. The majority of parallel import of medicinal products related cases in the Court of Justice of the European Union (hereinafter – CJEU) are dealing with barriers for parallel trade that occur in license issuance procedure. Therefore, the main goal of this article is to identify and analyse regulatory peculiarities of parallel import of medicinal products licence (hereinafter – parallel import licence or licence) issuance procedure that may create barriers for the parallel trade of medicinal products in the Republic of Lithuania. In order to achieve this task, the article evaluates the necessity of parallel import licence, analyses separate elements of this procedure, identifies its regulatory peculiarities and discusses whether these regulatory peculiarities are acceptable for the EU law.
The article concludes that domestic law of the Republic of Lithuania creates challenges for a parallel trader, as the EU law and the CJEU jurisprudence were not taken into account during the implementation of sufficient similarity criteria. A lack of detailed secondary legislation together with administrative problems may reduce the accessibility of the procedure and challenge the implementation of the requirement of the CJEU that this procedure should last “a reasonable time”.

**Keywords:** parallel import, licence, medicinal products, pharmaceutical law, EU law.

**Introduction**

According to Article 2 part 57 of the Law on Pharmacy of the Republic of Lithuania, parallel import of medicinal products means “import into the Republic of Lithuania outside the distribution network of the authorised distributor of the product granted marketing authorisation in another EEA Member State, which is identical to the medicinal product already granted marketing authorisation in the Republic of Lithuania or sufficiently resembling it”\(^1\). The same definition of parallel import is used in the EU law\(^2\). Article 17 of the above mentioned law that took force in 2006 defines the main conditions for parallel import and licence issuance procedure. However, parallel import of medicinal products is still at the rudimental stage in Lithuania. There are 229 medicinal products (this number includes variations) on the List of Parallel Import Medicinal Products\(^3\). The number of legal entities operating in the aerie of parallel import of medicinal products is also very limited.

On the other hand, it is problematic that parallel import of medicinal products is regulated by common norms of the primary EU law only, i.e. the parallel import is based on Article 34 (ex. 28) of the Treaty on the Functioning of the European Union\(^4\) (hereinafter – TFEU) and is subject to the derogations regarding the protection of human health and life and the protection of industrial and commercial property, as defined by Article 36 (ex. 30) of the TFEU. No special secondary legislation addresses the issue of parallel trade of medicinal products and the jurisprudence of the CJEU proofs that EU Member States differently interpret the primary law of the EU and so create obstacles for parallel trade of medicinal products. There are several cases at the Court of Justice of the

---


European Union that are closely connected with domestic requirements of Member States for parallel import licence issuance procedure\(^5\), \(^6\), \(^7\), \(^8\), \(^9\).

It may be hypothetically presumed that Lithuanian regulation may also create barriers for parallel trade of medicinal products in Lithuania that cannot be justified with the help of derogations defined in Article 36 of the TFEU. These barriers may make parallel import less attractive for legal entities and lead to a smaller number of parallel import medicinal products than in neighbouring EU countries with nearly the same pharmaceutical marked, e.g., there are 305 parallel import medicinal products (including variations) in the Register of Human Medicines in Latvia\(^10\). Respectively, questions may arise whether the current Lithuanian regulation is economically well grounded and whether it corresponds to the officially declared aims of national pharmaceutical policy that identifies priorities, such as reduction of prices of medicinal products and improvement of access to medicinal products, as well\(^11\). Meanwhile, parallel import, as such, is undoubtedly capable to achieve the above mentioned aims and current data show that the parallel trade industry has provided about 2.5 billion savings for Member States during the period of 2004–2009 and this trend is likely to be sustained in the future\(^12\), \(^13\), \(^14\). However, neither Lithuanian regulation of parallel trade of medicinal products, nor the economic consequences of it have been systematically analysed in scientific works in Lithuania\(^15\).

\(^5\) Case 104/75, de Peijper [1976] ECR 00613.
\(^7\) Case C-112/02, Kohlpharma [2004] ECR I-03369.
\(^8\) Case C-113/01, Paranova Oy [2003] ECR I-04243.
\(^9\) Case C-212/03, Commission of the European Communities v French Republic [2005] ECR I-04213.
\(^11\) Lietuvos Respublikos Seimo 2003 m. birželio 5 d. nutarimas Nr. IX-1604 „Dėl Lietuvos nacionalinės vaistų politikos nuostatų patvirtinimo“. Valstybės žinios. 2003, Nr.56-2488.
Therefore, the main object of this article is regulation of parallel import of medicinal products license issuance procedure. The goal of the article is to identify and analyse regulatory peculiarities of parallel import of medicinal products licence issuance procedure that may create barriers for the parallel trade of medicinal products in the Republic of Lithuania. The following tasks are expected to be achieved:

1) evaluate the necessity of parallel import licence;
2) analyse the separate elements of the licence issuance procedure and identify its regulatory peculiarities;
3) evaluate whether regulatory peculiarities identified in task II are acceptable according to the EU law.

Systematic and comparative analyses together with the method of synthesis are going to be used in this article.

1. Necessity of Parallel Import Licence Issuance Procedure

A medicinal product may be put on the market of the EU Member State, when a marketing authorisation was granted at a national level in accordance with the provisions of the Directive 2001/83/EC16 or at the Community level in accordance with the provisions of Regulation 2309/9317. The main purpose of the above mentioned EU legal norms is the protection of public health. Thus, an obligation to obtain a marketing authorisation does not contradict the principle of free movement of goods.

However, parallel trade of medicinal products occurs, when a marketing authorisation has already been granted by several Member States and a medicinal product is lawfully on their market. In this case, competent authorities of Member States possess all the documents that were submitted by the marketing authorisation holder before the authorisation was granted; they have evaluated these documents and have made a decision that a medicinal product is safe for human use. Therefore, the question is whether an additional licence is necessary for the parallel import product and if this question is answered in negative, how the safety of a parallel import product (and protection of public health) must be guaranteed. These issues were addressed by the EUCJ in Centrafarm v Sterling Drug and de Peijper cases.

The court in Centrafarm v Sterling Drug had pointed out that there is a risk to import defective products and, therefore, “the protection of the public against risks arising from defective pharmaceutical products is a matter of legitimate concern, and article 30 [now article 36] of the treaty authorizes the Member States to derogate from the rules concerning the free movement of goods on grounds of the protection of health and life of humans and animals”18. The Court has also explained, that “the measures necessary to achieve this must be such as may properly be adopted in the field of health control

18 Supra note 6, para. 27.
However, the Court abstained from explanation what is being meant by “the measures necessary to achieve” and what are “properly adopted” measures. On the other hand, it may be observed, that the CJEU has agreed that Member States can adopt some national rules that are aimed at the protection of human health in case of parallel import of medicinal products.

The jurisprudence of the CJEU had a possibility to develop further in de Peijper. The facts of this case were significantly stimulating this development: a Dutch importer, Adriaan de Peijper, was prosecuted for importing a medicinal product from the UK without the approval of the Dutch competent authorities and without possessing either the product marketing authorization documents or the batch records.

The court recognised that as all relevant documents were already held by competent authorities, they should cooperate in making these documents available to each other. If the parallelly traded and nationally authorised products were slightly different, it was up to the national competent authorities to investigate whether this difference was therapeutically significant. The only measures, which a national authority was justified in taking, were those intended to verify the identity of the product or sufficient similarity and the same therapeutical effect. In conclusion, national competent authorities may not create barriers for parallel import of medicinal products by requesting parallel importers to satisfy the same requirements that are applicable to legal entities placing the product on the national market for the first time. A parallel importer is entitled to rely on medicinal product safety data collected at the expense of a marketing authorisation holder and the burden of proof rests on competent authorities. So, the CJEU has highlighted that the principle of relaxation of controls by national authorities in Member States is closely related to the principle of their cooperation.

Following the de Peijper judgement, the European Commission announced a Communication on Parallel Imports of Proprietary Medicinal Products in 1982, outlining basic principles of parallel import of medicinal products and the EU Member States were able to start developing simplified procedures for the parallel import license issuance.
Later on, in case *Commission v France*, the Court has also acknowledged that the lack of national regulatory framework (absence of a simplified license issuance procedure for parallel import of medicinal products for plant protection) causes a failure of a Member State to fulfil its obligations under Article 28 (now Article 34 of the TFEU)\(^{28}\). It may be assumed from the above mentioned case, that a free movement of medicinal products creates a duty for a Member State to establish a certain regulatory framework. In such a case, there could be a legal problem with the evaluation of Lithuanian regulation just after the accession to the EU. Legal prerequisites for parallel trade of medicinal products for human use were established in 2006, when Law on Pharmacy took force, i.e., two years after Lithuania became the EU Member State. The issuance of licenses started in 2007, only when a specific simplified procedure was developed by the Ministry of Health\(^{29}\). Furthermore, no specific procedure for parallel import of medicinal products for animal use or plant protection has been developed up to now.

### 2. Eligibility Criteria Applicable to Parallel Import Medicinal Products

According to the Law on Pharmacy Art. 17 para. 3–4, medicinal products may be imported to the Republic of Lithuania, when they 1) are included into the List of Parallel Import Medicinal Products and 2) have a valid license for parallel import. Eligible for parallel import are only those medicinal products that are 1) identical to the medicinal product already registered in the Republic of Lithuania or 2) sufficiently similar to it. Medicinal products are considered sufficiently similar if they meet the following eligibility criteria:

1. the same active substance and the same salt of the active substance, the same ester, ether, isomer or mixtures of isomers, complexes or derivatives of an active substance of isomers;
2. the same strength;
3. the same pharmaceutical form and administration method;
4. the same clinical and pharmaceutical properties. Bioequivalence to a proprietary medicinal product with marketing authorisation in Lithuania is obligatory when a medicinal product to-be-imported is generic. In case a product with marketing authorisation in Lithuania and a product to-be-imported both are generics, they have to be bioequivalent to the same proprietary medicinal product\(^{30}\).

Neither the Law on Pharmacy, nor secondary legislation does not provide any clarity how the evaluation of sufficient similarity should be done and how the requirement for the products to be “the same” (in Lithuanian “tas pats”) has to be interpreted in practice. Licensing procedure that was approved by the head of State Medicines Control Agency at the Ministry of Health of the Republic of Lithuania limits itself by stating that a senior

---


\(^{29}\) Sveikatos apsaugos ministro 2007 m. balandžio 5 d. įsakymas Nr. V-228 „Dėl vaistinių preparatų lygiagretaus importo taisyklų patvirtinimo“. *Valstybės žinios*. 2007, Nr. 39-1456.

\(^{30}\) *Supra* note 1, Art. 17, para. 3–4.
specialist evaluates whether the medicinal product is sufficiently similar to the product that has a marketing authorisation in Lithuania and makes a reference to two legal acts that have to be used for this evaluation: Law on Pharmacy and the Decree of the Minister of Health on the Rules of Parallel Import of Medicinal Products. However, neither of these two legal acts provides any details on the processes of evaluation of sufficient similarity.

So, it might be assumed that there are no other rules of procedure and this means that an evaluation of similarity and an interpretation of criteria are left upon a person, who is applying the law. When technically important definition of “the same” is not fixed by the national law, a person applying the law is free to interpret “the same” (in Lithuanian “tas pats”) as “identical in all aspects”. Therefore, it could be acknowledged that the implementation of the rules of procedure by the SMCA did not solve the issue, which was raised by the Special Investigation Service in 2010, when it came to the conclusion that the regulation of license issuance procedure is not clear enough and is lacking transparency.

On the other hand, criteria of sufficient similarity were addressed in numerous cases of the CJEU. Therefore, the article further will focus on the analysis of these cases, as it may deepen an understanding of problems with Lithuanian domestic regulation and may clarify whether an interpretation of “the same” as “identical in all aspects” is possible from the perspective of the EU law.

2.1. CJEU Jurisprudence on Eligibility Criteria Applicable to Parallel Import Medicinal Products

In de Peijper, the Court addressed a situation, when a qualitative and quantitative composition of a medicinal product imported by a parallel importer were different from those of a medicinal product that had marketing authorisation in a country of destination, when “the differences between the one and the other product are of such minor importance that it is likely that the manufacturer is applying or introducing .... these differences with the conscious and exclusive intention of using these differences .... in order to prevent or impede the possibility of the parallel importation of the proprietary medicinal product”. De Peijper judgment concluded that the above mentioned variants of an already authorised medicinal product can be treated as similar to a product in a country of destination and may be imported in parallel as long as there are no differences of therapeutic significance between these products. The meaning of “qualitative and quantitative differences in...”

34 Supra note 5, para. 33.
composition” was left by the Court unexplained. The explanation of it may be found in other cases of the CJEU. The case Smith & Nephew demands that the two products do not have to be identical in all respects, but they 1) should be manufactured according to the same formulation, 2) using the same active ingredient, and that 3) have the same therapeutic effect. This requirement was recited in the Communication of the Commission, too. However, there is a slight difference between the Communication and the CJEU ruling. It is a requirement of a common origin, that was not included into the Communication, but actually is a part of the judgement in case Smith & Nephew and the judgement requires that manufacturers of both products in question should be part of the same group of undertakings or that they produce those medicinal products under agreements with the same licensor.

The jurisprudence of the Court had a possibility to develop further in Rhône-Poulenc Rorer and May § Baker judgement. According to this judgement, a medicinal product may be regarded as sufficiently similar if a parallel imported product has the same active ingredients and therapeutic effect as a product with marketing authorisation, but does not use the same excipient and is manufactured by a different manufacturing process, provided that both products have the same therapeutic effect and the marketing authorisations referred to above are granted to different members of the same group of companies and manufacturers of both medicinal products belong to the same group. Furthermore, a parallel import licence remains valid even if a marketing authorisation was withdrawn in a Member State of destination. According to the CJEU, a Competent Authority in a Member State of destination, that is granting a license for parallel trade, should be in a position to verify that medicinal product to be imported complies with requirements relating to quality, efficacy and safety, and should be in a position to ensure normal pharmacovigilance. Thus, the Court followed its practice in de Peijper case and repeated that qualitative differences (in this case, this is a difference in excipients) do not preclude products to be called “sufficiently similar” for the purpose of parallel trade and their composition is regarded in this case as being “the same”. It may be also observed that the Court in Rhône-Poulenc Rorer and May § Baker judgement used common origin criteria as one of the elements that are necessary for the evaluation of sufficient similarity of proprietary medicinal products and clearly defined obligations of a Competent Authority that is assessing a request to grant a parallel import license.

In case Paranova Oy, the Court recognised that the difference in a pharmaceutical form (tablets versus capsules) and composition of active substance (omeprazole acid in capsules versus magnesium salt of omeprazole acid in tablets) do not make these products incomparable for the purpose of parallel import, provided that their therapeutic effect is the same (both products have the same dose of the active substance, which is absorbed

---

37 Commission of the European Communities, supra note 2, p. 8.
at the same rate and to the same extent)\textsuperscript{40}. Thus, it may be concluded that these two products – tablets and capsules – were regarded \textit{de facto} as “sufficiently similar”, even though the court did not use this wording in \textit{expressis verbis}.

Several major changes in a licence issuance procedure occurred after the \textit{Kohlpharma} case. Here, the court addressed the requirement of the common origin that was used by Member States for the comparison of “sufficient similarity”. However, despite the existing practice, the court refused to acknowledge the requirement of the common origin as a necessary requirement for the evaluation of a sufficient similarity of a medicinal product to be imported and pointed out that “In the case where an application for a marketing authorisation for a medicinal product is submitted with reference to a medicinal product that has already been authorised;

- the medicinal product which is the subject of the application is imported from a Member State in which it has obtained a marketing authorisation;
- the assessment of safety and efficacy carried out for the medicinal product which is already authorised can be used in the application for a marketing authorisation for the second medicinal product without the risk to public health.” \textsuperscript{41}

According to the Court, Articles 34 and 36 of the TFEU preclude the application being rejected solely on the ground that the two medicinal products do not have a common origin\textsuperscript{42}. However, the Court suggested that a common origin can be “an important element” in determining comparability of two products, when a Competent Authority in a Member State has to evaluate whether the safety and efficacy assessment carried out for the medicinal product, which has already been authorised in a Member State, can be applied to the product that is going to be imported\textsuperscript{43}. In such a way, the \textit{Kohlpharma} judgement opened the gate for the parallel import of generic medicinal products. On the other hand, this judgment created uncertainty that is widely discussed among scientists\textsuperscript{44}. There are even doubts if mutual recognition is needed for generic medicinal products, when a product approved in one Member State could be placed on the market of another one by obtaining a simplified license for parallel import that is based on the approval received by the marketing authorisation holder of the proprietary product in a Member State of destination\textsuperscript{45}. On the other hand, the judgement did not tackle the issue of pharmacovigilance and, therefore, it is not clear how pharmacovigilance should be guaranteed when common origin of the product is missing.

\textsuperscript{40} Supra note 8, para. 14–15. It should be noted, that the difference in active substance was introduced by the manufacturer because of technical reasons only. It was easier to manufacture tablets than capsules since the salt dissolves more easily in water and is more stable.

\textsuperscript{41} Supra note 7, para. 21.

\textsuperscript{42} Ibid.

\textsuperscript{43} Ibid., para. 17.


A common origin was also addressed in case *Commission of the European Communities v French Republic*. This case relates to plant protection products. The law of France required that both a product imported in parallel and a product with marketing authorization in France should have a common origin. The Commission considered that this requirement is a restriction on free movement of goods, which is contrary to Article 34 of the TFEU. The Commission in its decision explicitly relied on the *Kohlpharma* judgement. However, the CJEU pointed out the differences between the EU legislation applicable to medicinal products for human use and to plant protection products respectively and has made a conclusion that a requirement of common origin for plant protection products cannot be considered as contrary to Article 34 of the TFEU\(^46\). Thus, different levels of regulation of various types of medicinal products may result in different rules for the evaluation of their sufficient similarity. However, the questions raised by the *Kohlpharma* judgement and the emphasis on a common origin in the judgement *Commission of the European Communities v French Republic* let us presume that there is a huge possibility of future litigations and that the Court will probably come back to the issue of a common origin when addressing sufficient similarity.

### 2.2. Eligibility Criteria Applicable to Parallel Import Medicinal Products in Lithuanian National Law and Possible Barriers for Parallel Trade

Turning back to the domestic law, it should be observed that it took nearly 5 years for Lithuania to start using the *Kohlpharma* judgement as a basis for legislation. Debates about the implementation of this judgement started in 2010 with the new draft of the Law on Pharmacy that took force in January 2012\(^47\). However, the problems with parallel import of generic medicinal products still remain. Systematic analysis of Articles 17 and 11 of the Law on Pharmacy shows that there could be some doubts about the legitimacy of parallel trade of generic medicinal products, as Article 17 paragraph 4 part 1 is left unchanged and *the same* salt of the active substance, the same ester, ether, isomer or mixtures of isomers, complexes or derivatives of an active substance of isomers are still required during evaluation of sufficient similarity. This may create barriers for parallel import of some generic products, because according to the Article 11 paragraph 8, a proprietary medicinal product and a bioequivalent generic product *may have different* salts, esters, ethers, etc.

The above analysis of the jurisprudence of the CJEU (especially the position of the Court in cases *Paranova Oy* and *De Peijper*) also supports the conclusion that barriers for parallel trade may occur with the national requirement for “the same strength” and “the

\(^46\) *Supra* note 28, para. 20, 30–40.

same pharmaceutical form”\textsuperscript{48}, when strength and form have no influence on a therapeutic effect and safety of a product. Furthermore, the interpretation of “sufficient similarity” in the domestic law may be one of the reasons leading to a low number of parallel import medicinal products in Lithuania, as it limits a number of products that are eligible for parallel trade. In practice, there have already been cases, when a parallel import licence was refused for products that are put on the market as “powder with solvent” in country of export and marketed as “powder” in Lithuania\textsuperscript{49}. It should be observed that both products have had the same therapeutic effect.

On the other hand, while reflecting potential problems with the requirement of “the same strength” and “the same form” in the domestic law, it should be noted that marketing authorisation holders take different measures aimed at limiting parallel import, e.g., in 1989-1993, company Bayer introduced 24 different versions of the medicinal product called Adalat in the EU countries (all versions had different form and/or strength) with the aim to eliminate the possibility that those products will be evaluated as sufficiently similar for the purpose of parallel trade\textsuperscript{50}. Therefore, the review of the domestic law and elimination of those norms that are inconsistent with the EU law and can aggravate the evaluation of sufficient similarity providing surplus requirements are inevitable measures that may facilitate parallel trade and help to increase the availability of low price medicinal products.

3. “Reasonable Time” and “Accessibility” of Parallel Import License Procedure

According to the CJEU, a national procedure that regulates the issuance of licenses for parallel import of medicinal products in a Member State of destination is supposed to be easily accessible (in French \textit{facilement accessible}) and should “last a reasonable time” (in French \textit{dans un délai raisonnable})\textsuperscript{51}. However, the Court has never explained in expressis verbis how accessibility and a reasonable time of the procedure are understood.

Reasonable time of the procedure was addressed by the European Commission in its Communication only. The European Commission pointed out that Directive 2001/83 defines a 90 days period, within which a Member State may decide on a recognition of a marketing authorisation issued by another Member State\textsuperscript{52}. Therefore, the Commission suggests that the period of 45 days may be a reasonable time limit for a simplified procedure in case of parallel import. The same time limit of the procedure is defined by the national law\textsuperscript{53}. This period begins when the Competent Authority (State Medicines Control Agency

\textsuperscript{48} Supra note 1, Art. 17, para. 3–4.


\textsuperscript{50} Supra note 44, p. 12.

\textsuperscript{51} Supra note 28, para. 21; Supra note 9, para. 45–49.

\textsuperscript{52} Supra note 2, p. 7.

\textsuperscript{53} Supra note 1, Art. 17, para. 7.
in Lithuania) accepts an application submitted according to the requirements established by the Minister of Health. The time spent by an applicant for provision of additional documents and necessary explanations required by the State Medicines Control Agency is not included in a 45 days period. No other time limit is defined in a secondary legislation, e.g., it is not clear in how many days the State Medicines Control Agency is obliged to review an application and make a decision that this application is submitted according to the national requirements; it is not clear when the State Medicines Control Agency has to contact a Competent Authority in a Member State of origin. The time needed for a communication with a Competent Authority in a Member State of origin may also exceed a period of 45 days, as the EU law does not define an exact number of days that is given to a Competent Authority in a Member State of origin for the preparation of documents that need to be sent for a review in a Member State of destination. On the other hand, only two persons at the State Medicines Control Agency are responsible for the evaluation of medicinal products, which are to be imported, and the issuance of licenses. Furthermore, parallel import related duties are not their only duties at the State Medicines Control Agency. Thus, the capacities of the staff are rather limited. Therefore, the 45 days period is much longer in practice and in some instances it is significantly longer than the period needed for a marketing authorisation issuance procedure (e.g., a simplified procedure may take up to 580 days). These facts suggest that domestic regulation of a license issuance procedure needs to be improved by adding specific deadlines, e.g., the ones for formal evaluation of documents submitted. On the other hand, administrative measures at the State Medicines Control Agency can be also reconsidered, as a limited number of staff employed and its constant overload with other duties may influence the functionality of an existing procedure.

Conclusions

1. A simplified parallel import license issuance procedure is a legitimate procedure based on Article 36 of the TFEU, as it ensures that parallel import products are not risky to the health and life of humans. Due to the need to ensure the same therapeutic effect, a number of parallel import medicinal products is limited to products that are regarded as identical or sufficiently similar if compared with the products marketed in a Member State of destination.

2. The EUCJ has developed a set of rules used for the comparison of sufficient similarity of products to be imported. Products having the same active substance, the same formulation and the same therapeutic effect are undoubtedly treated as sufficiently similar. However, it may be observed in the jurisprudence that wording “the same” does not mean “identical in all aspects” and there may be cases, when differences in an active substance (e.g., acid and salt of that acid) and in a pharmaceutical form (e.g., tablets

---


55 Supra note 48.
versus capsules) or in a quantity of an active substance may be regarded to be of minor importance and, therefore, products are treated as sufficiently similar for the purpose of parallel trade, provided that their therapeutic effect remains identical.

3. The EU law and the CJEU jurisprudence were not taken into consideration during the development of sufficient similarity criteria in Lithuania. This especially applies to the requirements of the same pharmaceutical form and the same strength. A lack of detailed secondary legislation together with administrative problems, such as a lack of personnel, may reduce the accessibility of the procedure and challenge the implementation of the requirement that the procedure should last “a reasonable time”. Therefore, legislative measures should be taken in order to make a license issuance procedure more flexible and sufficient similarity criteria need to be adapted to the jurisprudence of the CJEU.

References

Case C-201/06, *Commission of the European Communities v French Republic* [2008] ECR I-00735.


Širinskienė, A.; Zalepūga, M. Lygiagrečiai importuojamų vaistinių preparatų kai-
Mindaugas Zalepūga. Legal Requirements for Parallel Import of Medicinal Products ...

REIKALAVIMAI ŽMOGUĮ SKIRTŲ VAISTINIŲ PREPARATŲ LYGIAGRETAUS IMPORTO LEIDIMŲ IŠDAVIMUI IR GALIMOS LYGIAGRETAUS IMPORTO Į LIETUVOS RESPUBLIKĄ KLIŪTYS

Mindaugas Zalepūga
Mykolo Romerio universitetas, Lietuva


Valstybinės vaistų kontrolės prie Lietuvos Respublikos Sveikatos apsaugos ministerijos viršininko 2010 m. spalio 11 d. įsakymas Nr. P-587 „Dėl lygiagrečiai importuojamų vaistinių preparatų registruojimo procedūros patvirtinimo“. Dokumento žymuo: 4/P-10:2010-10-1.
Siekiant užsibrėžto tikslo straipsnyje pirmiausia analizuojama, ar valstybėse narėse taikoma leidimų sistema yra būtina ir priimtina ES teisės atžvilgiu. Padarius išvadą, jog ši sistema nesukelia ES teisės pažeidimo, nagrinėjami atskiri leidimų sistemos elementai, daugiausiai dėmesio skiriant vaistinių preparatų pakankamo panašumo vertinimo kriterijų analizei. Straipsnyje, remiantis Europos Sąjungos Teisingumo Teismo jurisprudencija, atkreipiamas dėmesys į tai, jog atskirų pakankamo panašumo vertinimo kriterijų (pvz., identiškos vaistinio preparato formos, identiško veikliosios medžiagos kiekio kiekių reikalavimai) taikymas gali pažeisti laisvo prekių judėjimo principą. Taip pat analizuojami ir leidimų išdavimo terminai bei administracinio pobūdžio aprūpomai.

Daroma išvada, jog rengiant nacionalinės teisės aktus, reguliuojančius lygiagretaus vaistinių preparatų importo leidimo išdavimo sistemą, o ypač nustatant pakankamo panašumo kriterijus, nebuvo atsižvelgta į Europos Sąjungos Teisingumo Teismo praktiką. Išsamaus pojūtymo reglamentavimo trūkumas drauge su administracinėmis problemomis – personalo stygiumi – gali apsunkinti lygiagretaus vaistinių preparatų leidimų išdavimo prieinamumą ir kelti problemų siekiant, kad leidimai būtų išduodami „per protingą laiką tarpą“, kaip kad reikalauja Europos Sąjungos Teisingumo Teismas. Todėl įstatymų leidėjas, atsizvelgiant į Europos Sąjungos Teisingumo Teismo praktiką, reikėtų svarstyti apie Lietuvos Respublikos farmacijos įstatymo pataisas, kuriomis būtų įgyventinti minėtojo teismo sprendimai, susiję su vaistinių preparatų pakankamo panašumo vertinimu.

**Reikšminiai žodžiai:** lygiagretus importas, leidimas, vaistinis preparatas, farmacijos teisė, ES teisė.

---

**Mindaugas Zalepūga.** Mykolo Romerio universiteto Teisės fakulteto Teisės filosofijos ir istorijos katedros doktorantas. Mokslių tyrės kryptys: bioteisė, farmacijos teisė.

**Mindaugas Zalepūga.** Mykolas Romeris University, Faculty of Law, Department of Legal Philosophy and History, PhD student. Research interests: biolaw, pharmaceutical law.